Aspect Biosystems successfully raised US$115 million Series B financing to proceed with bioprinted tissue therapeutics development. 

Aspect Biosystems is a biotechnology company that is developing technology to help incurable diseases such as Type 1 diabetes. Their innovation is designed to replace, repair, or supplement biological functions inside the body. Through the integration of proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials, they are creating these next-generation cell therapies by applying their full-stack tissue therapeutic platform.

They were a company in VentureLabs’ Venture Acceleration Program and Go To Market Program.

“I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases,” said Tamer Mohamed, Founder and CEO, Aspect Biosystems.

Read the full article on BC Business.

Image sourced from BC Business.